Yahoo Finance

Needham lowered the firm’s price target on RxSight (RXST) to $43 from $66 and keeps a Buy rating on the shares as part of a broader research note on MedTech/Diagnostics sector. Following the recent pre-announcements and management commentary, the firm is updating its forecasts on select names while also rolling forward its valuation framework to 2026 estimates, the analyst tells investors in a research note.

Invest with Confidence:

• Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.

• Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on RXST:

• RxSight price target lowered to $40 from $42 at Wells Fargo

• RxSight sees FY25 revenue $185M-$197M, consensus $187.35M

• RxSight reports preliminary Q4 revenue $40.2M, consensus $40.39M

• RxSight downgraded to Hold from Buy at Stifel

• Needham ups Alcon target, adds to Conviction List